Quizartinib (AC220)

中文名称:奎扎替尼

Quizartinib (AC220)是一种二代FLT3抑制剂,作用于Flt3(ITD/WT),在MV4-11和 RS4;11细胞中IC50分别为1.1 nM/4.2 nM,作用于Flt3比作用于KIT,PDGFRA,PDGFRB,RET,和CSF-1R选择性高10倍。Quizartinib (AC220)可诱导肿瘤细胞的凋亡。Phase 3。

Quizartinib (AC220) Chemical Structure

Quizartinib (AC220) Chemical Structure

CAS: 950769-58-1

规格 价格 库存 购买数量
10mM (1mL in DMSO) RMB 1056.51 现货
5mg RMB 876.33 现货
50mg RMB 4234.23 现货
200mg RMB 10565.1 现货
更大包装 有超大折扣

400-668-6834

info@selleck.cn

免费分装
免费预溶

客户使用Selleck的Quizartinib (AC220)发表文献133

产品质控

批次: 纯度: 99.52%
99.05

Quizartinib (AC220)相关产品

Target Protein Ligand抑制剂选择性比较

细胞实验数据示例

细胞系 实验类型 给药浓度 孵育时间 活性描述 文献信息
8226/MR20 Cell Viability Assays 0.1 µM 96 h sensitizes K562/ABCG2 cells to mitoxantrone topotecan  23967177
K562/ABCG2 Cell Viability Assays 0.1/0.5/1 µM 96 h sensitizes K562/ABCG2 cells to mitoxantrone topotecan  23967177
MCF-7 FLV1000 Kinase Assay 0–30 µM 5 min decreases [125I]-IAAP photolabeling of ABCB2 at IC50 of 0.07 μM 23967177
MCF-7 FLV1000 Kinase Assay 0–30 µM 5 min decreases [125I]-IAAP photolabeling of ABCB1 at IC50 of 3.3 μM 23967177
K562/ABCG2 Function Assay 0.1-10 μM 30 min enhances uptake of substrates of ABCG2 and ABCB1 in a concentration-dependent manner 23967177
8226/MR20  Function Assay 0.1-10 μM 30 min enhances uptake of substrates of ABCG2 and ABCB1 in a concentration-dependent manner 23967177
K562/ABCB1 Function Assay 0.1-10 μM 30 min enhances uptake of substrates of ABCG2 and ABCB1 in a concentration-dependent manner 23967177
HL60/VCR Function Assay 0.1-10 μM 30 min enhances uptake of substrates of ABCG2 and ABCB1 in a concentration-dependent manner 23967177
MV4-11 Antitumor assay 10 mg/kg 60 days Antitumor activity against human MV4-11 cells xenografted mouse model assessed as inhibition of tumor regrowth at at 10 mg/kg, po 60 days post treatment 19654408
MV4-11 Antitumor assay 1 mg/kg/day 30 days Antitumor activity against human MV4-11 cells xenografted mouse bone marrow engraftment model assessed as increase mouse life span at 1 mg/kg/day, po for 30 days measured on day 77 post dose 19654408
MV4-11 Antitumor assay 1 mg/kg 28 days Antitumor activity against human MV4-11 cells xenografted in athymic nude mouse assessed as inhibition of tumor growth at 1 mg/kg, po QD for 28 days measured during dosing period 19754199
MV4-11 Antitumor assay 3 mg/kg 28 days Antitumor activity against human MV4-11 cells xenografted in athymic nude mouse assessed as tumor growth regression at 3 mg/kg, po QD for 28 days measured after dosing period 19754199
MV4-11 Antitumor assay 10 mg/kg 28 days Antitumor activity against human MV4-11 cells xenografted in athymic nude mouse assessed as tumor growth regression at 10 mg/kg, po QD for 28 days measured after dosing period 19754199
MV4-11 Antitumor assay 3 mg/kg 28 days Antitumor activity against human MV4-11 cells xenografted in athymic nude mouse assessed as suppression of tumor volume at 3 mg/kg, po QD for 28 days measured after dosing period 19754199
MV4-11 Antitumor assay 10 mg/kg 28 days Antitumor activity against human MV4-11 cells xenografted in athymic nude mouse assessed as suppression of tumor volume at 10 mg/kg, po QD for 28 days measured after dosing period 19754199
MV4-11 Antitumor assay 10 mg/kg 28 days Antitumor activity against human MV4-11 cells xenografted in athymic nude mouse assessed as inhibition of tumor growth at 10 mg/kg, po QD for 28 days measured after 32 days postdose 19754199
MV4-11 Antitumor assay 10 mg/kg 48 days Antitumor activity against human MV4-11 cells xenografted in nude mouse assessed as tumor regression at 10 mg/kg, po qd administered on day 1 to 5 measured during 48 days post last dose 26081023
MV4-11 Antitumor assay 10 mg/kg 48 days Antitumor activity against human MV4-11 cells xenografted in nude mouse assessed as tumor regression at 10 mg/kg, po qd administered on day 8 to 12 measured during 48 days post last dose 26081023
MOLM13 Cell cycle assay 100 nM 12 hrs Cell cycle arrest in human MOLM13 cells assessed as accumulation at G0/G1 phase at 100 nM after 12 hrs by propidium iodide staining based-FACS analysis 28956923
MOLM14 Cell cycle assay 100 nM 12 hrs Cell cycle arrest in human MOLM14 cells assessed as accumulation at G0/G1 phase at 100 nM after 12 hrs by propidium iodide staining based-FACS analysis 28956923
MOLM13 Apoptosis assay 100 nM 12 hrs Induction of apoptosis in human MOLM13 cells assessed as cleavage of PARP at 100 nM after 12 hrs by immunoblotting method 28956923
MV4-11 Apoptosis assay 100 nM 48 hrs Induction of apoptosis in human MV4-11 cells assessed as cleavage of PARP at 100 nM after 48 hrs by immunoblotting method 28956923
MOLM13 Apoptosis assay 100 nM 12 hrs Induction of apoptosis in human MOLM13 cells assessed as cleavage of caspase-3 at 100 nM after 12 hrs by immunoblotting method 28956923
MOLM14 Apoptosis assay 100 nM 24 hrs Induction of apoptosis in human MOLM14 cells assessed as cleavage of PARP at 100 nM after 24 hrs by immunoblotting method 28956923
MOLM14 Apoptosis assay 100 nM 24 hrs Induction of apoptosis in human MOLM14 cells assessed as cleavage of caspase-3 at 100 nM after 24 hrs by immunoblotting method 28956923
MV4-11 Apoptosis assay 100 nM 48 hrs Induction of apoptosis in human MV4-11 cells assessed as cleavage of caspase-3 at 100 nM after 48 hrs by immunoblotting method 28956923
MV4-11 Cell cycle assay 100 nM 12 hrs Cell cycle arrest in human MV4-11 cells assessed as accumulation at G0/G1 phase at 100 nM after 12 hrs by propidium iodide staining based-FACS analysis 28956923
MV4-11 Function assay 0.01 to 100 nM 1 hr Inhibition of FLT3 ITD mutant in human MV4-11 cells assessed as decrease in AKT phosphorylation at S473 at 0.01 to 100 nM after 1 hr by immunoblot analysis 29672049
MV4-11 Function assay 0.01 to 100 nM 1 hr Inhibition of FLT3 ITD mutant in human MV4-11 cells assessed as decrease in MEK1/2 phosphorylation at S217/221 at 0.01 to 100 nM after 1 hr by immunoblot analysis 29672049
MV4-11 Function assay 1 nM 1 hr Inhibition of FLT3 ITD mutant autophosphorylation at Y589/591 in human MV4-11 cells at 1 nM after 1 hr by immunoblot analysis 29672049
MV4-11 Function assay 1 nM 1 hr Inhibition of FLT3 ITD mutant autophosphorylation at Y842 in human MV4-11 cells at 1 nM after 1 hr by immunoblot analysis 29672049
MV4-11 Function assay 0.01 to 100 nM 1 hr Inhibition of FLT3 ITD mutant in human MV4-11 cells assessed as decrease in STAT5 phosphorylation at Y694 at 0.01 to 100 nM after 1 hr by immunoblot analysis 29672049
MV4-11 Function assay 0.01 to 100 nM 1 hr Inhibition of FLT3 ITD mutant in human MV4-11 cells assessed as decrease in ERK1/2 phosphorylation at T202/Y204 at 0.01 to 100 nM after 1 hr by immunoblot analysis 29672049
MV4-11 Function assay 10 mg/kg 24 hrs In vivo inhibition of FLT3 ITD mutant in human MV4-11 cells xenografted in athymic nu/nu mouse assessed as decrease in STAT5 phosphorylation at Y694 at 10 mg/kg, ip after 24 hrs by immunoblot method relative to control 29672049
MV4-11 Function assay 0.1 uM 4 hrs Inhibition of FLT3 in human MV4-11 cells assessed as reduction in AKT phosphorylation at Ser473 residue at 0.1 uM after 4 hrs by Western blot analysis 29894944
MV4-11 Function assay 0.1 uM 4 hrs Inhibition of FLT3 in human MV4-11 cells assessed as reduction in STAT5 phosphorylation at Tyr694 residue at 0.1 uM after 4 hrs by Western blot analysis 29894944
MV4-11 Function assay 0.1 uM 4 hrs Inhibition of FLT3 in human MV4-11 cells assessed as reduction in ERK1/2 phosphorylation at Thr202/Tyr204 residues at 0.1 uM after 4 hrs by Western blot analysis 29894944
MV4-11 Function assay 0.1 uM 4 hrs Inhibition of FLT3 phosphorylation at Tyr589/591 residues in human MV4-11 cells at 0.1 uM after 4 hrs by Western blot analysis 29894944
MV4-11 Growth Inhibition Assay 72 h IC50=0.3 nM 23412931
MOLM-14 Growth Inhibition Assay 72 h IC50=0.1 nM 23412931
SEM-K2 Growth Inhibition Assay 72 h IC50=0.4 nM 23412931
RS4;11 Growth Inhibition Assay 72 h IC50>10,000 nM 23412931
THP-1 Growth Inhibition Assay 72 h IC50>10,000 nM 23412931
MV4-11 Apoptosis Assay 8/24 h induces significant and dose-dependent PARP cleavage and accumulation of sub-2N DNA 23412931
MOLM-14 Apoptosis Assay 8/24 h induces significant and dose-dependent PARP cleavage and accumulation of sub-2N DNA 23412931
SEM-K2 Apoptosis Assay 8/24 h induces significant and dose-dependent PARP cleavage and accumulation of sub-2N DNA 23412931
MV4-11 Cytotoxicity assay 72 hrs Cytotoxicity against human MV4-11 cells after 72 hrs by cell titer-blue assay, IC50 = 0.00056 μM. 19654408
blast cells Function assay 2 hrs Inhibition of FLT3 ITD mutant autophosphorylation in human blast cells after 2 hrs by electrochemiluminescence, IC50 = 0.0008 μM. 19654408
RS4-11 Function assay 2 hrs Inhibition of FLT3 ITD mutant autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay, IC50 = 0.0011 μM. 19654408
RS4-11 Function assay 2 hrs Inhibition of FLT3 autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay, IC50 = 0.0042 μM. 19654408
MV4-11 Antiproliferative assay 72 hrs Antiproliferative activity against human MV4-11 cells after 72 hrs by cell titer-blue cell viability assay, IC50 = 0.00056 μM. 19754199
MV411 Growth inhibition assay 48 hrs Growth inhibition of human MV411 cells after 48 hrs by XTT assay, GI50 = 3.31 μM. 25108079
THP1 Growth inhibition assay 48 hrs Growth inhibition of human THP1 cells after 48 hrs by XTT assay, GI50 = 5.574 μM. 25108079
HL60 Growth inhibition assay 48 hrs Growth inhibition of human HL60 cells after 48 hrs by XTT assay, GI50 = 8.014 μM. 25108079
32D Function assay 72 hrs Inhibition of human FLT3 ITD mutant expressed in mouse 32D cells assessed as cell growth inhibition after 72 hrs by MTS assay, GI50 = 0.00001 μM. 26081023
MV4-11 Function assay 72 hrs Inhibition of FLT3 ITD homozygous mutant in human MV4-11 cells assessed as cell growth inhibition after 72 hrs by MTS assay, GI50 = 0.003 μM. 26081023
MOLM-13 Function assay 72 hrs Inhibition of FLT3 ITD heterozygous mutant in human MOLM-13 cells assessed as cell growth inhibition after 72 hrs by MTS assay, GI50 = 0.004 μM. 26081023
32D Function assay 72 hrs Inhibition of drug resistant human FLT3 ITD D835Y mutant expressed in mouse 32D cells assessed as cell growth inhibition after 72 hrs by MTS assay, GI50 = 0.016 μM. 26081023
32D Function assay 72 hrs Inhibition of drug resistant human FLT3 ITD D835V mutant expressed in mouse 32D cells assessed as cell growth inhibition after 72 hrs by MTS assay, GI50 = 0.027 μM. 26081023
Sf9 Function assay 4 hrs Inhibition of wild type GST-tagged FLT3 kinase domain (Y567 to S993) (unknown origin) expressed in baculovirus infected insect Sf9 cells using Her2 peptide as substrate after 4 hrs by Kinase-Glo assay, IC50 = 0.069 μM. 26081023
32D Function assay 72 hrs Inhibition of drug resistant human FLT3 ITD D835F mutant expressed in mouse 32D cells assessed as cell growth inhibition after 72 hrs by MTS assay, GI50 = 0.15 μM. 26081023
32D Function assay 72 hrs Inhibition of drug resistant human FLT3 ITD F691L mutant expressed in mouse 32D cells assessed as cell growth inhibition after 72 hrs by MTS assay, GI50 = 0.22 μM. 26081023
Sf9 Function assay 120 mins Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay, IC50 = 0.43 μM. 26081023
RS4:11 Function assay 72 hrs Inhibition of wild type homozygous FLT3 in human RS4:11 cells assessed as cell growth inhibition after 72 hrs by MTS assay, GI50 = 2.2 μM. 26081023
MV4-11 Cytotoxicity assay 72 hrs Cytotoxicity against human MV4-11 cells incubated for 72 hrs by MTT assay, IC50 = 0.00068 μM. 26142317
Sf21 Function assay 15 mins Inhibition of recombinant human FLT3 expressed in insect Sf21 cells preincubated for 15 mins followed by poly(Glu:Tyr) substrate addition for 30 mins in presence of [gamma-32P]ATP by TR-FRET assay, IC50 = 0.02608 μM. 27187860
MV4-11 Growth inhibition assay 48 hrs Growth inhibition of human MV4-11 cells expressing FLT3-ITD after 48 hrs by XTT assay, GI50 = 1.103 μM. 27187860
HL60 Growth inhibition assay 48 hrs Growth inhibition of human HL60 cells expressing wild type FLT-3 after 48 hrs by XTT assay, GI50 = 1.488 μM. 27187860
THP1 Growth inhibition assay 48 hrs Growth inhibition of human THP1 cells expressing wild type FLT-3 after 48 hrs by XTT assay, GI50 = 2.125 μM. 27187860
K562 Growth inhibition assay 48 hrs Growth inhibition of human K562 cells after 48 hrs by XTT assay, GI50 = 2.638 μM. 27187860
Sf21 Function assay 10 mins Inhibition of N-terminal GST-tagged recombinant human wild-type FLT3 (564 to end residues) expressed in baculovirus infected sf21 cells using Abltide as substrate in presence of [gamma33P]ATP after 10 mins by scintillation counting method, IC50 = 0.0255 μM. 28043794
Sf21 Function assay 10 mins Inhibition of N-terminal GST-tagged recombinant human wild-type FLT3 (564 to end residues) D835Y mutant expressed in baculovirus infected sf21 cells using Abltide as substrate in presence of [gamma33P]ATP after 10 mins by scintillation counting method, IC50 = 0.2355 μM. 28043794
BAF3 Antiproliferative assay 72 hrs Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-D835G mutation after 72 hrs by CellTiter-Glo assay, GI50 = 0.0003 μM. 28956923
BAF3 Antiproliferative assay 72 hrs Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-D835A mutation after 72 hrs by CellTiter-Glo assay, GI50 = 0.0003 μM. 28956923
BAF3 Antiproliferative assay 72 hrs Antiproliferative activity against mouse BAF3 cells harboring FLT3-D835H mutation after 72 hrs by CellTiter-Glo assay, GI50 = 0.0003 μM. 28956923
MOLM13 Antiproliferative assay 72 hrs Antiproliferative activity against human MOLM13 cells harboring FLT3-ITD mutation after 72 hrs by CellTiter-Glo assay, GI50 = 0.0003 μM. 28956923
BAF3 Antiproliferative assay 72 hrs Antiproliferative activity against mouse BAF3 cells expressing TEL-fused FLT3 kinase after 72 hrs by CellTiter-Glo assay, GI50 = 0.0003 μM. 28956923
BAF3 Antiproliferative assay 72 hrs Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-D835N mutation after 72 hrs by CellTiter-Glo assay, GI50 = 0.0003 μM. 28956923
MOLM14 Antiproliferative assay 72 hrs Antiproliferative activity against human MOLM14 cells harboring FLT3-ITD mutation after 72 hrs by CellTiter-Glo assay, GI50 = 0.0003 μM. 28956923
BAF3 Antiproliferative assay 72 hrs Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD mutation after 72 hrs by CellTiter-Glo assay, GI50 = 0.0003 μM. 28956923
MV4-11 Antiproliferative assay 72 hrs Antiproliferative activity against human MV4-11 cells after 72 hrs by CellTiter-Glo assay, GI50 = 0.0003 μM. 28956923
BAF3 Antiproliferative assay 72 hrs Antiproliferative activity against TEL-fused PDGFRalpha-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay, GI50 = 0.0003 μM. 28956923
BAF3 Antiproliferative assay 72 hrs Antiproliferative activity against mouse BAF3 cells harboring FLT3-D835Y mutation after 72 hrs by CellTiter-Glo assay, GI50 = 0.002 μM. 28956923
BAF3 Antiproliferative assay 72 hrs Antiproliferative activity against TEL-fused PDGFRbeta-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay, GI50 = 0.0044 μM. 28956923
BAF3 Antiproliferative assay 72 hrs Antiproliferative activity against mouse BAF3 cells harboring FLT3-D835V mutation after 72 hrs by CellTiter-Glo assay, GI50 = 0.011 μM. 28956923
BAF3 Antiproliferative assay 72 hrs Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-D835del mutation after 72 hrs by CellTiter-Glo assay, GI50 = 0.012 μM. 28956923
Sf9 Function assay 1 hr Inhibition of human MV4-11 cells-derived His-tagged FLT3 ITD mutant (564 to 993 residues) expressed in baculovirus infected sf9 cells using poly (4:1 Glu, Tyr) as substrate after 1 hr by ADP-Glo kinase assay, IC50 = 0.0168 μM. 28956923
BAF3 Antiproliferative assay 72 hrs Antiproliferative activity against TEL-fused cKIT-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay, GI50 = 0.017 μM. 28956923
BAF3 Antiproliferative assay 72 hrs Antiproliferative activity against TEL-fused CSF1R-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay, GI50 = 0.024 μM. 28956923
BAF3 Antiproliferative assay 72 hrs Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-D835Y mutation after 72 hrs by CellTiter-Glo assay, GI50 = 0.028 μM. 28956923
Sf9 Function assay 1 hr Inhibition of human HL60 cells-derived His-tagged FLT3 (564 to 993 residues) expressed in baculovirus infected sf9 cells using poly (4:1 Glu, Tyr) as substrate after 1 hr by ADP-Glo kinase assay, IC50 = 0.0304 μM. 28956923
BAF3 Antiproliferative assay 72 hrs Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-D835I mutation after 72 hrs by CellTiter-Glo assay, GI50 = 0.056 μM. 28956923
BAF3 Antiproliferative assay 72 hrs Antiproliferative activity against TEL-fused DDR2-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay, GI50 = 0.11 μM. 28956923
BAF3 Antiproliferative assay 72 hrs Antiproliferative activity against TEL-fused DDR1-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay, GI50 = 0.12 μM. 28956923
CMK Antiproliferative assay 72 hrs Antiproliferative activity against human CMK cells expressing FLT3 kinase after 72 hrs by CellTiter-Glo assay, GI50 = 0.12 μM. 28956923
BAF3 Antiproliferative assay 72 hrs Antiproliferative activity against TEL-fused RET-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay, GI50 = 0.13 μM. 28956923
HL60 Antiproliferative assay 72 hrs Antiproliferative activity against human HL60 cells expressing FLT3 kinase after 72 hrs by CellTiter-Glo assay, GI50 = 0.13 μM. 28956923
BAF3 Antiproliferative assay 72 hrs Antiproliferative activity against TEL-fused FLT4-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay, GI50 = 0.27 μM. 28956923
BAF3 Antiproliferative assay 72 hrs Antiproliferative activity against mouse BAF3 cells harboring FLT3-K663Q mutation after 72 hrs by CellTiter-Glo assay, GI50 = 0.37 μM. 28956923
BAF3 Antiproliferative assay 72 hrs Antiproliferative activity against TEL-fused LCK-transformed mouse BAF3 cells after 72 hrs by CellTiter-Glo assay, GI50 = 0.4 μM. 28956923
U937 Antiproliferative assay 72 hrs Antiproliferative activity against human U937 cells expressing FLT3 kinase after 72 hrs by CellTiter-Glo assay, GI50 = 1.2 μM. 28956923
SKM1 Antiproliferative assay 72 hrs Antiproliferative activity against human SKM1 cells expressing FLT3 kinase after 72 hrs by CellTiter-Glo assay, GI50 = 1.3 μM. 28956923
NB4 Antiproliferative assay 72 hrs Antiproliferative activity against human NB4 cells expressing FLT3 kinase after 72 hrs by CellTiter-Glo assay, GI50 = 7.3 μM. 28956923
MOLM13 Growth inhibition assay 72 hrs Growth inhibition of human MOLM13 cells after 72 hrs by calcein AM dye-based fluorescence assay, GI50 = 0.002 μM. 29672049
MV4-11 Growth inhibition assay 72 hrs Growth inhibition of human MV4-11 cells after 72 hrs by calcein AM dye-based fluorescence assay, GI50 = 0.003 μM. 29672049
BA/F3 Function assay 72 hrs Inhibition of FLT3 ITD mutant (unknown origin) transfected in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by calcein AM dye-based fluorescence assay, GI50 = 0.007 μM. 29672049
Kasumi-1 Growth inhibition assay 72 hrs Growth inhibition of human Kasumi-1 cells after 72 hrs by calcein AM dye-based fluorescence assay, GI50 = 0.064 μM. 29672049
BA/F3 Growth inhibition assay 72 hrs Growth inhibition of mouse BA/F3 cells after 72 hrs by calcein AM dye-based fluorescence assay, GI50 = 1.452 μM. 29672049
Pat.375 Growth Inhibition Assay IC50=503 nM 23497317
Pat.305 Growth Inhibition Assay IC50=7079 nM 23497317
Pat.299 Growth Inhibition Assay IC50=7248 nM 23497317
Pat.279 Growth Inhibition Assay IC50=3434 nM 23497317
Pat.221 Growth Inhibition Assay IC50=675 nM 23497317
MOLM14 Growth Inhibition Assay IC50< 1 nM 23497317
MV4;11 Growth Inhibition Assay IC50< 1 nM 23497317
EOL-1 Growth Inhibition Assay IC50=1 nM 23497317
M-07e + SCF Growth Inhibition Assay IC50=77 nM 23497317
Kasumi-1 Growth Inhibition Assay IC50=36 nM 23497317
p815 Growth Inhibition Assay IC50=445 nM 23497317
HMC1.2 Growth Inhibition Assay IC50=1727 nM 23497317
HMC1.1 Growth Inhibition Assay IC50=14 nM 23497317
Pat.379 Growth Inhibition Assay IC50=806 nM 23497317
Pat.368 Growth Inhibition Assay IC50=2700 nM 23497317
Pat.601 Growth Inhibition Assay IC50=1153 nM 23497317
HMC1.1 Apoptosis Assay IC50=31 nM 23497317
p815 Apoptosis Assay IC50=341 nM 23497317
Kasumi-1 Apoptosis Assay IC50=67 nM 23497317
M-07e + SCF Apoptosis Assay IC50=78 nM 23497317
EOL-1 Apoptosis Assay IC50< 1 nM 23497317
MV4;11 Apoptosis Assay IC50=2 nM 23497317
MOLM14 Apoptosis Assay IC50=3 nM 23497317
GIST822 Apoptosis Assay IC50=109 nM 23497317
Pat.368 Apoptosis Assay IC50=2998 nM 23497317
Pat.601 Apoptosis Assay IC50=876 nM 23497317
AML Cytotoxicity assay Cytotoxicity against human AML cells isolated from relapsed acute myeloid leukemia patient harboring FLT3 ITD mutation by MTT assay, IC50 = 0.0003 μM. 19654408
AML Function assay Inhibition of FLT3 autophosphorylation in human AML cells isolated from relapsed acute myeloid leukemia patient by Western blotting, IC50 = 0.002 μM. 19654408
HEK293 Function assay Binding affinity to FLT3 catalytic domain expressed in HEK293 cells by competitive binding assay, Kd = 0.0016 μM. 19754199
MOLM13 Antiproliferative assay Antiproliferative activity against human MOLM13 cells expressing FLT3-ITD mutant, GI50 = 0.004 μM. 22726931
MV4-11 Growth inhibition assay Growth inhibition of human MV4-11 cells harboring FLT3-ITD mutant by XTT assay, GI50 = 1.103 μM. 28043794
THP1 Growth inhibition assay Growth inhibition of human THP1 cells harboring wild-type FLT3 by XTT assay, GI50 = 2.125 μM. 28043794
Saos-2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells 29435139
MG 63 (6-TG R) qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells 29435139
BT-12 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells 29435139
LAN-5 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells 29435139
DAOY qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells 29435139
U-2 OS qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells 29435139
Rh41 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 29435139
NB-EBc1 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells 29435139
NB1643 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells 29435139
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells 29435139
Sf9 Function assay Inhibition of N-terminal GST/His6-fused recombinant human FLT3 (R571 to S993 residues) ITD mutant expressed in Sf9 insect cells using poly (Ala,Glu,Lys,Tyr) 6:2:5:1 hydrobromide as substrate in presence of [gamma-33P]ATP, IC50 = 0.01 μM. 29672049
Sf9 Function assay Inhibition of N-terminal GST/His6-fused recombinant wild type human FLT3 (R571 to S993 residues) expressed in Sf9 insect cells using poly (Ala,Glu,Lys,Tyr) 6:2:5:1 hydrobromide as substrate in presence of [gamma-33P]ATP, IC50 = 0.036 μM. 29672049
Sf9 Function assay Inhibition of N-terminal GST/His6-fused recombinant human FLT3 (R571 to S993 residues) D835Y mutant expressed in Sf9 insect cells using poly (Ala,Glu,Lys,Tyr) 6:2:5:1 hydrobromide as substrate in presence of [gamma-33P]ATP, IC50 = 0.136 μM. 29672049
点击查看更多细胞系数据

生物活性

产品描述 Quizartinib (AC220)是一种二代FLT3抑制剂,作用于Flt3(ITD/WT),在MV4-11和 RS4;11细胞中IC50分别为1.1 nM/4.2 nM,作用于Flt3比作用于KIT,PDGFRA,PDGFRB,RET,和CSF-1R选择性高10倍。Quizartinib (AC220)可诱导肿瘤细胞的凋亡。Phase 3。
特性 AC220是二代FLT3抑制剂,且作为临床FLT3抑制剂的第一候选药。
靶点
FLT3 (ITD) [1]
(MV4-11 cells)
FLT3 (WT) [1]
(RS4;11 cells)
1.1 nM 4.2 nM
体外研究(In Vitro)
体外研究活性 AC220是最有效的FLT3选择性抑制剂,可用于治疗急性骨髓性白血病(AML)。AC220在生化和细胞实验中具有低纳摩尔效果和特别的激酶选择性,抑制大部分人类蛋白激酶时具有高选择性。AC220是治疗急性骨髓性白血病(AML)的新型FLT3抑制剂。[1]
激酶实验 激酶实验
为了测定AC220抑制无靶点激酶的效果,为了比较AC220和其他FLT抑制剂的选择性,使AC220作用于KinomeScan一组402种激酶进行结合试验,其中80%为典型的人类蛋白激酶。测定所有激酶的解离常数。计算绝对选择性和作用于FLT的相对选择性。
细胞实验 细胞系 MV4-11和RS4;11细胞
浓度 0-100 nM
孵育时间 72小时,及2小时
方法 在增殖实验中,细胞培养在低血清培养基(含0.5% FBS)中过夜, 然后按每孔4×104个细胞接种在96孔板上,然后加入AC220,37oC下温育72小时。测定细胞活力。测定抑制FLT3自磷酸化的效果, 细胞培养在低血清培养基(含0.5% FBS)过夜,然后按每孔4×105个细胞接种在96孔板上。细胞和AC220一起在37oC下温育2小时,诱导 RS4;11细胞中FLT3自磷酸化, 加入100 ng/mL FLT3配位体,持续15分钟。转移细胞溶解物到用FLT3抗体包被的96孔板上。然后加入作用于FLT3的生物素化抗体,测定全部FLT3,或者作用于磷酸酪氨酸的抗体,测定FLT3自磷酸化。使用 SULFO标记的链霉亲和素二抗进行电化学发光测定。
实验图片 检测方法 检测指标 实验图片 PMID
Western blot p-STAT5 / STAT5 / β-catenin / p-AKT / AKT / p-ERK / ERK / p-S6 / S6 phospho-FLT3 / FLT3 28625976
Immunofluorescence WGA / FLT3 28895560
Growth inhibition assay Cell viability 23967177
体内研究(In Vivo)
体内研究活性 AC220作用于移植瘤模型,具有好的药品属性,极高的药效和耐受性。在体内,AC220作用于FLT3-ITD AML鼠模型,抑制FLT3活性,明显延长寿命;作用于依赖FLT3的移植瘤鼠模型时,根除肿瘤;作用于病人原代细胞时,有效抑制FLT3活性。[1]
动物实验 Animal Models 雌性裸鼠或严重联合免疫缺陷鼠
Dosages 10 mL/kg
Administration 口服饲喂处理
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04473664 Completed
Hepatic Impairment|Moderate Impaired Hepatic Function
Daiichi Sankyo Inc.
September 22 2020 Phase 1
NCT04459585 Completed
Healthy Subjects|Drug-drug Interaction|Pharmacokinetics|Quizartinib
Daiichi Sankyo Co. Ltd.|Daiichi Sankyo Inc.
August 28 2020 Early Phase 1
NCT04459598 Completed
Healthy Subjects|Drug-drug Interaction|Pharmacokinetics|Quizartinib
Daiichi Sankyo Co. Ltd.|Daiichi Sankyo Inc.
August 19 2020 Phase 1
NCT04209725 Terminated
Leukemia Myeloid Acute
SCRI Development Innovations LLC
June 3 2020 Phase 2
NCT03552029 Terminated
Acute Myeloid Leukemia
Daiichi Sankyo Inc.
December 12 2018 Phase 1

化学信息&溶解度

分子量 560.67 分子式

C29H32N6O4S

CAS号 950769-58-1 SDF Download Quizartinib (AC220) SDF
Smiles CC(C)(C)C1=CC(=NO1)NC(=O)NC2=CC=C(C=C2)C3=CN4C5=C(C=C(C=C5)OCCN6CCOCC6)SC4=N3
储存条件(自收到货起)

体外溶解度
批次:

DMSO : 100 mg/mL ( 178.35 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO)

Water : Insoluble

Ethanol : Insoluble

摩尔浓度计算器

体内溶解度
批次:

现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂

动物体内配方计算器

实验计算

摩尔浓度计算器

质量 浓度 体积 分子量

动物体内配方计算器(澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)

mg/kg g μL

第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)

% DMSO % % Tween 80 % ddH2O
%DMSO %

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于μL DMSO溶液(母液浓度mg/mL,:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);

体内配方配制方法:μL DMSO母液,加入μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入μL ddH2O,混匀澄清。

体内配方配制方法:μL DMSO母液,加入μL Corn oil,混匀澄清。

注意:1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

* 必填项

请输入您的姓名
请输入您的邮箱地址 请输入一个有效的邮箱地址
请写点东西给我们

常见问题及建议解决方法

问题 1:
Is it possible to alter the captisol concentration to make it more dissolvable i.e 20% or 25% captisol ?

回答:
In 15% Captisol, the compound forms s suspension at 30mg/ml. Increasing the percentage of Captisol will not convert the mixture into solution. You can use suspension for oral gavage feeding.

Tags: buy Quizartinib (AC220) | Quizartinib (AC220) ic50 | Quizartinib (AC220) price | Quizartinib (AC220) cost | Quizartinib (AC220) solubility dmso | Quizartinib (AC220) purchase | Quizartinib (AC220) manufacturer | Quizartinib (AC220) research buy | Quizartinib (AC220) order | Quizartinib (AC220) mouse | Quizartinib (AC220) chemical structure | Quizartinib (AC220) mw | Quizartinib (AC220) molecular weight | Quizartinib (AC220) datasheet | Quizartinib (AC220) supplier | Quizartinib (AC220) in vitro | Quizartinib (AC220) cell line | Quizartinib (AC220) concentration | Quizartinib (AC220) nmr
在线咨询
联系我们